Jennifer Mandal

Goodwin

Contact
View Bio
RSS

Latest Posts › Biosimilars

Share:

Regulatory Update on Alvotech’s AVT02, a High-Concentration Interchangeable Adalimumab Biosimilar

On September 20, Alvotech announced that FDA has accepted the resubmission of its Biologics License Application (BLA) for AVT02, a high concentration, interchangeable biosimilar to HUMIRA (adalimumab). FDA has set a...more

10/3/2023  /  Biologics , Biosimilars , Food and Drug Administration (FDA) , Interchangeability , Pharmaceutical Industry , Prescription Drugs
1 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide